Document is current
Any future updates will be listed below
-
Authors
Chen, Kai
Martens, Yuka A.
Meneses, Axel
Ryu, Daniel H.
Lu, Wenyan
Raulin, Ana Caroline
Li, Fuyao
Zhao, Jing
Chen, Yixing
Jin, Yunjung
Linares, Cynthia
Goodwin, Marshall
Li, Yonghe
Liu, Chia-Chen
Kanekiyo, Takahisa
Holtzman, David M.
Golde, Todd E.
Bu, Guojun
-
Funding
Funding for this research was provided by:
NIH (P01NS074969, P01NS074969, U19AG069701, U19AG069701)
Mayo Alzheimer’s Disease Research Center Developmental Grant
Lewy Body Dementia Center Without Walls (U54NS110435, U54NS110435)
- License Information
-
More Information
Article History
Received: 31 May 2022
Accepted: 9 August 2022
First Online: 2 September 2022
Declarations
:
: Not applicable.
: All authors agreed to publish.
: G.B. consults for SciNeuro, has consulted for AbbVie, E-Scape, Eisai, and Vida Ventures and is on the scientific advisory board for Kisbee Therapeutics. D.M.H. is as an inventor on a patent licensed by Washington University to C2N Diagnostics on the therapeutic use of anti-tau antibodies. D.M.H. co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Genentech, Denali and Cajal Neuroscience and consults for Alector. All other authors declare no competing interests.
